Tobacco Carcinogen And Nicotine Metabolism: Implications For Tobacco-Related Cancer Risk Assessment And Tobacco Cessation
A Special Presentation By Dr. Philip Lazarus, PhD
April 5, 2016, 10:30 a.m. | RG 6040
Tobacco use and cigarette smoking is the single leading cause of preventable disease and mortality in the United States. Dr. Lazarus and his team have spent the past 25 years exploring pathways by which nicotine and major tobacco carcinogens are metabolized. He and his team have studied the major tobacco-specific nitrosamine, NNK, and examined the role of genetic variation on tobacco-related cancer risk. Dr. Lazarus will present studies focused on analyzing urinary tobacco carcinogen metabolites as potential phenotypic markers of cancer risk, phase II metabolism pathways, genotype-phenotype relationships within these pathways, and the development of novel agents for tobacco cessation.
About Dr. Philip Lazarus, PhD
Dr. Philip Lazarus is the Boeing Distinguished Professor and Chair of Pharmaceutical Sciences at Washington State University. Dr. Lazarus’ research has spanned the spectrum of cancer causation, prevention and treatment. He has focused on the elucidation of carcinogenic mechanisms with an underlying theme of cancer prevention, focusing primarily on mechanisms involved in the induction and progression of tobaccorelated cancers. Dr. Lazarus was the Associate Director of the Division of Population Sciences and Program Leader for the Cancer Prevention and Control Program at the Penn State Cancer Institute. He has a bachelor’s degree in human genetics and a Ph.D. in experimental medicine, both from McGill University in Montreal, Quebec, Canada.